Jaime Alberto Guajardo Lozano

Jaime Alberto Guajardo Lozano

Auto-generated profile, based on publicly available information

Jaime Alberto Guajardo Lozano

Tecnologico de Monterrey. Escuela de Medicina y Ciencias de la Salud., San Pedro Garza Garcia, Mexico

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
MCMauricio Castillo-Perez
Mauricio Castillo-Perez
CJCarlos Jerjes-Sanchez
Carlos Jerjes-Sanchez
ACAlejandra Castro-Varela
Alejandra Castro-Varela
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
EVEduardo Vázquez-Garza
Eduardo Vázquez-Garza
JPJathniel Panneflek
Jathniel Panneflek
To our knowledge, the treatment, outcome, clinical presentation, risk stratification of patients with venous thromboembolism and COVID-19 have not been well characterized. We searched for systematic reviews, cohorts, case series, case reports, editor letters, and venous thromboembolism COVID-19 patients’ abstracts following PRISMA and PROSPERO statements. We analyzed therapeutic approaches and clinical outcomes of venous thromboembolism COVID-19 patients. Inclusion: COVID-19 patients with venous thromboembolism confirmed by an imaging method (venous doppler ultrasound, ventilation-perfusion lung scan, computed tomography pulmonary angiogram, pulmonary angiography). We assessed and reported the original Pulmonary Embolism Severity Index for each pulmonary embolism patient. In addition, we defined major bleedings according to the International Society of Thrombosis and Haemostasis criteria. We performed a systematic review from August 9 to August 30, 2020. We collected 1,535 papers from PubMed, Scopus, Web of Science, Wiley, and Opengrey. We extracted data from 89 studies that describe 143 patients. Unfractionated and low-molecular-weight heparin was used as parenteral anticoagulation in 85/143 (59%) cases. The Food and Drug Administration-approved alteplase regimen guided the advanced treatment in 39/143 (27%) patients. The mortality was high (21.6%, CI 95% 15.2-29.3). The incidence of major bleeding complications was 1 (0.9%) in the survival group and 1 (3.2%) in the death group. Pulmonary Embolism Severity Index was class I in 11.6% and II in 22.3% in survivors compared to 0% and 6.5% in non-survivors, respectively. Patients who experienced venous thromboembolism events at home were more likely to live than in-hospital events. We determined a high mortality incidence of pulmonary embolism and a low rate of bleeding. Unfractionated and low-molecular-weight heparin drove parenteral anticoagulation and alteplase the advanced treatment in both groups. The original Pulmonary Embolism Severity Index could be helpful in the risk stratification.

1 May 2021 in JACC
Verified
Journal Article
Closed access
HGHector Lopez de la Garza
Hector Lopez de la Garza
GGGerardo Emilio Pozas Garza
Gerardo Emilio Pozas Garza
JZJose Gildardo Paredes-Vá Zquez
Jose Gildardo Paredes-Vá Zquez
HCHector Guillermo Betancourt Del Campo
Hector Guillermo Betancourt Del Campo
JLJaime Alberto Guajardo Lozano
Jaime Alberto Guajardo Lozano
CNCarlos Jerjes-Sá Nchez
Carlos Jerjes-Sá Nchez

1 May 2021 in JACC
Verified
Journal Article
Closed access
EPErasmo De La Pena-Almaguer
Erasmo De La Pena-Almaguer
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
MVMariana Vanoye-Tamez
Mariana Vanoye-Tamez
CMCecilia Marini
Cecilia Marini
JGJaime A. Guajardo-Lozano
Jaime A. Guajardo-Lozano
DMDaniela Mares-Custodio
Daniela Mares-Custodio